September 29-30, 2021
Presentation Title: Comprehensive immunogenomics to enable composite biomarkers for immunotherapy
Presenter: Travis Yates, PhD
Innovations to improve the prediction of patient response to immunotherapies requires a robust and comprehensive platform for tumor immunogenomic profiling. We hypothesize that a multidimensional approach examining several key areas of tumor-immune biology may provide benefit to predicting patient response to checkpoint inhibitors (CPI). In this presentation, we’ll highlight our recent publication exploring the analytical capabilities provided by immunogenomic profiling for understanding mechanisms of tumor evasion and creating composite biomarkers in a cohort of metastatic melanoma patients treated with CPIs. This works evaluates the predictive strength of a composite biomarker, neoantigen presentation score (NEOPS™) and demonstrates that an integrative approach outperforms single biomarkers by including tumor escape mechanisms. NEOPS illustrates that a data intensive biomarker can be clinically practical as well. Finally, we’ll touch on how combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT™ enables a broad view of the tumor and the immune-related components for hematological malignancies.